Compare QUALCOMM, Inc. (QCOM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs 10X Genomics Inc — how do they compare? QUALCOMM, Inc. trades at $176.01 (market cap $185.94B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: QUALCOMM, Inc. is far larger — about 21.7× 10X Genomics Inc's market cap, and QUALCOMM, Inc. pays a 2.11% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| QCOM | TXG | |
|---|---|---|
Market Cap | $185.94B | $8.55B |
Sector | Technology | Health |
52-Week High | $251.10 | $67.29 |
52-Week Low | $124.07 | $11.34 |
Enterprise Value | $192.90B | $8.08B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $176.4, up 4.54% today, with a bullish technical signal from moving averages and oscillators. The company reported revenue of $44.28B in 2025, with a net income margin of 21.01%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Analyst consensus is a Buy with a $200.56 price target, while news highlights AI and data center growth amid smartphone market challenges.
The outlook for QCOM is cautiously optimistic, driven by AI and data center expansion, but near-term risks include smartphone demand softness and margin pressures. Investment opportunity lies in diversification beyond handsets, though competition from Nvidia and Intel poses a threat. Earnings growth and execution on AI initiatives are key catalysts for upside.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
